Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Warts | 1 | 2025 | 17 | 0.960 |
Why?
|
| Cross Infection | 3 | 2013 | 344 | 0.950 |
Why?
|
| Trichosporonosis | 1 | 2024 | 8 | 0.920 |
Why?
|
| Acinetobacter Infections | 2 | 2013 | 36 | 0.780 |
Why?
|
| Wound Infection | 1 | 2022 | 54 | 0.770 |
Why?
|
| Acinetobacter baumannii | 2 | 2013 | 47 | 0.760 |
Why?
|
| Diabetic Foot | 1 | 2024 | 167 | 0.750 |
Why?
|
| Osteomyelitis | 1 | 2024 | 214 | 0.740 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2013 | 151 | 0.730 |
Why?
|
| Infectious Disease Medicine | 1 | 2021 | 11 | 0.720 |
Why?
|
| Podiatry | 1 | 2021 | 7 | 0.720 |
Why?
|
| Immunization, Passive | 8 | 2024 | 129 | 0.690 |
Why?
|
| Communicable Diseases | 1 | 2022 | 164 | 0.660 |
Why?
|
| Cooperative Behavior | 1 | 2021 | 233 | 0.640 |
Why?
|
| Ambulatory Care | 2 | 2022 | 414 | 0.590 |
Why?
|
| Hospitals, Psychiatric | 1 | 2012 | 68 | 0.390 |
Why?
|
| Carrier State | 1 | 2012 | 78 | 0.390 |
Why?
|
| Legionellosis | 1 | 2012 | 4 | 0.380 |
Why?
|
| Legionella | 1 | 2012 | 9 | 0.380 |
Why?
|
| Brain Abscess | 1 | 2012 | 54 | 0.360 |
Why?
|
| Infection Control | 1 | 2012 | 162 | 0.360 |
Why?
|
| Seasons | 1 | 2012 | 334 | 0.340 |
Why?
|
| Disease Outbreaks | 1 | 2012 | 330 | 0.340 |
Why?
|
| Endocarditis, Bacterial | 1 | 2012 | 138 | 0.340 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 230 | 0.330 |
Why?
|
| Wound Healing | 2 | 2025 | 488 | 0.330 |
Why?
|
| Prosthesis-Related Infections | 1 | 2012 | 188 | 0.310 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 573 | 0.280 |
Why?
|
| Hospitalization | 4 | 2024 | 1906 | 0.270 |
Why?
|
| Debridement | 1 | 2025 | 91 | 0.230 |
Why?
|
| Mental Disorders | 1 | 2012 | 887 | 0.230 |
Why?
|
| Basidiomycota | 1 | 2024 | 13 | 0.230 |
Why?
|
| Gangrene | 1 | 2024 | 27 | 0.230 |
Why?
|
| Outpatients | 5 | 2024 | 276 | 0.220 |
Why?
|
| Transfusion Reaction | 1 | 2023 | 40 | 0.210 |
Why?
|
| Humans | 21 | 2025 | 134156 | 0.210 |
Why?
|
| Urticaria | 1 | 2023 | 21 | 0.210 |
Why?
|
| Aged | 6 | 2024 | 21775 | 0.210 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2023 | 18 | 0.200 |
Why?
|
| JC Virus | 1 | 2023 | 29 | 0.200 |
Why?
|
| Antifungal Agents | 1 | 2024 | 305 | 0.190 |
Why?
|
| West Virginia | 1 | 2021 | 7 | 0.180 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2021 | 11 | 0.180 |
Why?
|
| Foot | 1 | 2021 | 65 | 0.170 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 1211 | 0.170 |
Why?
|
| Antiviral Agents | 1 | 2025 | 824 | 0.160 |
Why?
|
| Adult | 8 | 2025 | 31945 | 0.160 |
Why?
|
| Skin | 1 | 2022 | 545 | 0.160 |
Why?
|
| Neoplasms | 1 | 2013 | 3038 | 0.140 |
Why?
|
| Risk Factors | 3 | 2021 | 11182 | 0.140 |
Why?
|
| Male | 7 | 2025 | 66127 | 0.130 |
Why?
|
| Middle Aged | 5 | 2024 | 29399 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 2578 | 0.130 |
Why?
|
| Female | 7 | 2024 | 71928 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2013 | 3668 | 0.120 |
Why?
|
| Double-Blind Method | 3 | 2024 | 1665 | 0.110 |
Why?
|
| Skin Diseases, Infectious | 1 | 2012 | 25 | 0.100 |
Why?
|
| Pennsylvania | 1 | 2012 | 60 | 0.100 |
Why?
|
| Ofloxacin | 1 | 2012 | 32 | 0.090 |
Why?
|
| Medical Audit | 1 | 2012 | 104 | 0.090 |
Why?
|
| Endocardium | 1 | 2012 | 56 | 0.090 |
Why?
|
| Levofloxacin | 1 | 2012 | 48 | 0.090 |
Why?
|
| Nursing Homes | 1 | 2012 | 107 | 0.090 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2012 | 98 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 454 | 0.090 |
Why?
|
| Bacteriological Techniques | 1 | 2012 | 90 | 0.090 |
Why?
|
| Patient Admission | 1 | 2012 | 190 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 606 | 0.090 |
Why?
|
| Catheterization, Central Venous | 1 | 2012 | 139 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 333 | 0.090 |
Why?
|
| Deglutition Disorders | 1 | 2012 | 147 | 0.080 |
Why?
|
| Blood Transfusion | 1 | 2012 | 323 | 0.080 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 239 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2012 | 419 | 0.080 |
Why?
|
| Respiratory Tract Infections | 1 | 2012 | 294 | 0.080 |
Why?
|
| Radiography | 1 | 2012 | 826 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2021 | 17540 | 0.080 |
Why?
|
| Inpatients | 1 | 2013 | 547 | 0.080 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 394 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 362 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2022 | 13074 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 1218 | 0.070 |
Why?
|
| Cytokines | 2 | 2023 | 1401 | 0.070 |
Why?
|
| Critical Care | 1 | 2012 | 693 | 0.070 |
Why?
|
| United States | 4 | 2023 | 11763 | 0.060 |
Why?
|
| Echocardiography | 1 | 2012 | 1132 | 0.060 |
Why?
|
| Blood Donors | 1 | 2024 | 61 | 0.050 |
Why?
|
| Interleukin-7 | 1 | 2023 | 50 | 0.050 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2023 | 11 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2023 | 221 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 382 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 451 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 7217 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 825 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 446 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 204 | 0.040 |
Why?
|
| Syndrome | 1 | 2023 | 1167 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 497 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 3857 | 0.040 |
Why?
|
| Brain | 1 | 2012 | 3224 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2023 | 1627 | 0.040 |
Why?
|
| Young Adult | 1 | 2012 | 9944 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 1072 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1595 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2266 | 0.030 |
Why?
|
| Adolescent | 2 | 2023 | 20624 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1190 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2023 | 6601 | 0.020 |
Why?
|